FDA-approved profile

QVCAD System

QView Medical, Inc. · Ultrasound · FDA-approved (PMA)

Authorized purpose: The QVCAD System is indicated as an aid to the reader during screening procedures in searching images of female breasts produced by the somo.v Automated Breast Ultrasound System, for screening mammography BI-RADS Assessment Category 1 or 2 and BI-RADS composition or density c or d, to detect mammography-occult lesions in regions not known to have suspicious findings. The indicators are not intended for diagnostic characterization of suspicious findings.

Clinical role
Aid to the reader while searching 3D automated breast-ultrasound images for mammography-occult lesions.
Images and patients
Ultrasound · Female breasts; mammography-occult lesions in non-suspicious regions
Key limitation
Keep in mind: The PMA approval statement limits use to specified screening BI-RADS categories and breast densities; indicators are not intended for diagnostic characterization of suspicious findings.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: The QVCAD System is indicated as an aid to the reader during screening procedures in searching images of female breasts produced by the somo.v Automated Breast Ultrasound System, for screening mammography BI-RADS Assessment Category 1 or 2 and BI-RADS composition or density c or d, to detect mammography-occult lesions in regions not known to have suspicious findings. The indicators are not intended for diagnostic characterization of suspicious findings.
  • Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Female breasts; mammography-occult lesions in non-suspicious regions Input: Three-dimensional images of female breasts produced by the somo.v Automated Breast Ultrasound System.
  • Who uses it?Intended users: Qualified readers of screening Automated Breast Ultrasound System studies.
  • What does the software produce?Output: Indicators for regions not known to have suspicious findings.
  • What is its most important limitation?Key limitation: The PMA approval statement limits use to specified screening BI-RADS categories and breast densities; indicators are not intended for diagnostic characterization of suspicious findings.

Clinical takeaway. Clinical role: The QVCAD System is indicated as an aid to the reader during screening procedures in searching images of female breasts produced by the somo.v Automated Breast Ultrasound System, for screening mammography BI-RADS Assessment Category 1 or 2 and BI-RADS composition or density c or d, to detect mammography-occult lesions in regions not known to have suspicious findings. The indicators are not intended for diagnostic characterization of suspicious findings.

Evidence takeaway. Evidence from the reviewed source record: P150043 FDA decision material identifies the exact PMA-authorized breast ultrasound computer-aided detection device, labeled use, and submission-specific verification or approval evidence. It does not establish product-wide sensitivity, specificity, outcomes, or independent clinical validation beyond the exact evidence summarized here.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
The QVCAD System is indicated as an aid to the reader during screening procedures in searching images of female breasts produced by the somo.v Automated Breast Ultrasound System, for screening mammography BI-RADS Assessment Category 1 or 2 and BI-RADS composition or density c or d, to detect mammography-occult lesions in regions not known to have suspicious findings. The indicators are not intended for diagnostic characterization of suspicious findings.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Aid to the reader while searching 3D automated breast-ultrasound images for mammography-occult lesions.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Three-dimensional images of female breasts produced by the somo.v Automated Breast Ultrasound System.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Indicators for regions not known to have suspicious findings.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Screening workflows using the somo.v Automated Breast Ultrasound System.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Qualified readers of screening Automated Breast Ultrasound System studies.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
The PMA approval statement limits use to specified screening BI-RADS categories and breast densities; indicators are not intended for diagnostic characterization of suspicious findings.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
P150043 FDA decision material identifies the exact PMA-authorized breast ultrasound computer-aided detection device, labeled use, and submission-specific verification or approval evidence. It does not establish product-wide sensitivity, specificity, outcomes, or independent clinical validation beyond the exact evidence summarized here.
  • Exact FDA submission
  • Checked 2026-09-04

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
P150043 FDA decision material identifies the exact PMA-authorized breast ultrasound computer-aided detection device, labeled use, and submission-specific verification or approval evidence. It does not establish product-wide sensitivity, specificity, outcomes, or independent clinical validation beyond the exact evidence summarized here.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Sensitivity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, study design, and source if separately verified.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Specificity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, study design, and source if separately verified.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

P150043 FDA evidence package for QVCAD System

  • DesignOriginal PMA approval record and approval-order statement.
  • PopulationFemale breasts; mammography-occult lesions in non-suspicious regions
  • Scopeexact submission
  • Tested versionQVCAD System configuration described in P150043
  • IndependenceSponsor or vendor study

P150043

The PMA page warns that supplements may change device description or indication and lists supplement S001; this dossier is anchored to base PMA submission P150043 and does not infer supplement scope.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to P150043 by exact native submission identifier. This does not exclude product-family, later-version, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging or clinical service line and verify payer, site-of-service, coding, and coverage assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

This is not a product-specific reimbursement determination. Build a local total-cost and value model and verify payer, site-of-service, coding, and coverage assumptions independently.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Three-dimensional images of female breasts produced by the somo.v Automated Breast Ultrasound System.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA PMA P150043: QVCAD System

  2. Routing

    Source context, not route validation: The PMA record identifies the somo.v Automated Breast Ultrasound System as the source of the three-dimensional breast images; the current public PMA record does not establish broader interface, archive, or export behavior.

    Scope: Exact FDA submission. This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 · FDA PMA P150043: QVCAD System

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The exact public FDA decision material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 ·

  4. Returned objects

    Source context, not route validation: Indicators for regions not known to have suspicious findings.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA PMA P150043: QVCAD System

  5. Viewer/worklist/report

    Unresolved route: Indicators for regions not known to have suspicious findings.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA PMA P150043: QVCAD System

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
The PMA record identifies the somo.v Automated Breast Ultrasound System as the source of the three-dimensional breast images; the current public PMA record does not establish broader interface, archive, or export behavior.
  • Exact FDA submission
  • Checked 2026-09-04

This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.

Training
Only qualified readers of screening automated breast ultrasound system studies should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor P150043 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The PMA approval statement limits use to specified screening BI-RADS categories and breast densities; indicators are not intended for diagnostic characterization of suspicious findings.
  • Exact FDA submission
  • Checked 2026-09-04

This is buyer-facing monitoring guidance derived from the exact cleared or authorized scope; it is not a claim that the FDA package provides a live monitoring service.

Release and scope verification

Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to P150043 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that this cleared or authorized release includes them.

Deployment boundary

The exact public deployment topology remains incomplete; establish hosting responsibility, data flow, availability, upgrade, service, and downtime boundaries locally.

exact submission · checked 2026-09-04

FDA-described deployment boundaries do not establish current hosting contracts, security controls, uptime, or local qualification.

Interoperability acceptance

The PMA record identifies the somo.v Automated Breast Ultrasound System as the source of the three-dimensional breast images; the current public PMA record does not establish broader interface, archive, or export behavior.

exact submission · checked 2026-09-04

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The PMA approval statement limits use to specified screening BI-RADS categories and breast densities; indicators are not intended for diagnostic characterization of suspicious findings.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-04

No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.

Lifecycle monitoring

Monitor P150043 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The PMA approval statement limits use to specified screening BI-RADS categories and breast densities; indicators are not intended for diagnostic characterization of suspicious findings.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. PMA-authorized breast ultrasound computer-aided detection device limits remain submission-specific.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
P150043
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Ultrasound
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Female breasts; mammography-occult lesions in non-suspicious regions
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
PMA
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2016-11-09
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-approved
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
26Fields reviewed
11Source classes checked
2Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

Two PubMed records were screened. One identifies the QVCAD System but does not state a tested version or link the study to P150043, while the other does not establish the exact QVCAD configuration; both records are quarantined and none is promoted. The current discovery snapshot contains 2 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, fda decision material, fda pma record, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared or authorized configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Deployment: Not publicly available - checked 2026-09-04 - Exact FDA submission

    The exact public FDA decision material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not publicly available - checked 2026-09-04 - Exact FDA submission

    Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.

  • Installation timeline: Not yet reviewed

6 sources - 3 history items

Source ledger

  1. FDA PMA P150043: QVCAD System

    U.S. Food and Drug Administration - Published 2016-11-09 - Accessed 2026-09-04

    Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

Research history

  1. P150043 FDA decision

    Regulatory record

    PMA

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K242130

Koios DS

Koios Medical, Inc.

Authorized purpose: Koios Decision Support (DS) is an artificial intelligence (AI)/machine learning (ML)-based computer-aided diagnosis (CADx) software device intended for use as an adjunct to diagnostic ultrasound examinations of lesions or nodules suspicious for breast or thyroid cancer. Koios DS allows the user to select or confirm regions of interest (ROIs) within an image representing a single lesion or nodule to be analyzed. The software then automatically characterizes the selected image data to generate an AI/MLderived cancer risk assessment and selects applicable lexicon-based descriptors designed to improve overall diagnostic accuracy as well as reduce interpreting physician variability. Koios DS software may also be used as an image viewer of multi-modality digital images, including ultrasound and mammography. The software includes tools that allow users to adjust, measure and document images, and output into a structured report. Koios DS software is designed to assist trained interpreting physicians in analyzing the breast ultrasound images of adult (>= 22 years) female patients with soft tissue breast lesions and/or thyroid ultrasounds of all adult (>= 22 years) patients with thyroid nodules suspicious for cancer. When utilized by an interpreting physician who has completed the prescribed training, this device provides information that may be useful in recommending appropriate clinical management.

Modality
Ultrasound
Anatomy
Breast
Decision
2024-11-15
FDA-cleared K212616

Koios DS

Koios Medical, Inc.

Authorized purpose: Koios DS is an artificial intelligence (AI)/machine learning (ML)-based computer-aided diagnosis (CADx) software device intended for use as an adjunct to diagnostic ultrasound examinations of lesions or nodules suspicious for breast or thyroid cancer. Koios DS allows the user to select or confirm regions of interest (ROIs) within an image representing a single lesion or nodule to be analyzed. The software then automatically characterizes the selected image data to generate an AI/ML-derived cancer risk assessment and selects applicable lexicon-based descriptors designed to improve overall diagnostic accuracy as well as reduce interpreting physician variability. Koios DS may also be used as an image viewer of multi-modality digital images, including ultrasound and mammography. The software includes tools that allow users to adjust, measure and document images, and output into a structured report. Koios DS software is designed to assist trained interpreting physicians in analyzing the breast ultrasound images of adult (>= 22 years) female patients with soft tissue breast lesions and/or thyroid ultrasounds of all adult (>= 22 years) patients with thyroid nodules suspicious for cancer. When utilized by an interpreting physician who has completed the prescribed training, this device provides information that may be useful in recommending appropriate clinical management. Limitations: Patient management decisions should not be made solely on the results of the Koios DS analysis. Koios DS software is not to be used for the evaluation of normal tissue, on sites of post-surgical excision, or images with doppler, elastography, or other overlays present in them. Koios DS software is not intended for use on portable handheld devices (e.g. smartphones or tablets) or as a primary diagnostic viewer of mammography images. The software does not predict the presence of the thyroid nodule margin descriptor, extra-thyroidal extension. In the event that this condition is present, the user may select this category manually from the margin descriptor list.

Modality
Ultrasound
Anatomy
Breast
Decision
2021-12-16
FDA-cleared K161959

ClearView cCAD

ClearView Diagnostics Inc.

ClearView cCAD is a software application designed to assist skilled physicians in analyzing breast ultrasound images. It automatically classifies shape and orientation characteristics of user-selected regions of interest. this device uses multivariate pattern recognition methods to perform characterization and classification of images.

Modality
Ultrasound
Anatomy
Breast
Decision
2016-12-28
FDA-cleared K260234

MSK Go

Smart Alfa Teknoloji San. Ve Tic. A.S.

Authorized purpose: Assist qualified MSK-ultrasound professionals by highlighting supported joint anatomy and detection completeness on compatible adult ultrasound images; it is not a diagnostic device.

Modality
Ultrasound
Anatomy
Musculoskeletal joints: shoulder, elbow, wrist/hand, knee, and ankle/foot.
Decision
2026-05-21

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history